SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (758)12/2/1999 8:46:00 AM
From: RCMac  Read Replies (1) of 4474
 
ARIA announces extension of warrant expiration date
biz.yahoo.com

Thursday December 2, 8:04 am Eastern Time
Company Press Release
ARIAD Announces One Year Extension of the Expiration Date of Its Common Stock Purchase Warrants

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 2, 1999--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA - news) today announced that the exercise deadline for its Common Stock Purchase Warrants has been extended for a period of one year, from 5:00 p.m. New York City time on December 30, 1999 to 5:00 p.m. New York City time on December 30, 2000. The extension was effected by an amendment to the Warrant Agreement between ARIAD and the State Street Bank and Trust Company of Boston, Massachusetts, which acts as Warrant Agent for ARIAD's Common Stock Purchase Warrants.

All other terms of the Warrants remain unchanged. The Warrants are exercisable at $8.40 per share and are traded on the Nasdaq Market under the symbol: ARIAW.

ARIAD Pharmaceuticals (www.ariad.com ) is engaged in the discovery and development of novel therapeutics based on signal transduction technology. ARIAD is developing small-molecule drugs to block intracellular signaling pathways that play a critical role in major diseases, including osteoporosis and various immune-related disorders. ARIAD is also developing ARGENT(a), a proprietary gene regulation technology for orally active protein therapy and cellular immunotherapy that utilizes small-molecule drugs to control intracellular signaling pathways in engineered cells. [snip]
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News